Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
Noffar BarJoris DielsSuzy van SandenJoão MendesTeresa HernandoHeather BurnettPatricia CostJordan M SchecterNikoletta LendvaiNitin PatelTadao IshidaJeremy ErSimon J HarrisonNieves Lopez-MuñozPublished in: Current medical research and opinion (2024)
For patients with triple-class exposed RRMM treated with 2-4 prior lines of treatment, cilta-cel was found to provide superior clinical benefit over ide-cel in terms of response and progression-free survival.